You can access the annual and quarterly cash flow statements of Crescent Biopharma Ord Shs to evaluate its financial soundness and stability.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2025Q3
Operating cash flows (indirect method)
Cash flow from continuing operating activities
---17.54M
Net income from continuing operations
---24.61M
Operating gains losses
--28.00K
Other non-cash items
--94.00K
Change in working capital
--4.96M
-Change in prepaid expenses
--284.00K
-Change in other current assets
--47.00K
Cash from non-recurring investing activities
Cash from operating activities
---17.54M
Investing cash flow
Net cash from continuing investing activities
--586.00K
Capital expenditures
--586.00K
Net cash flow from disposal of fixed assets
--586.00K
Cash from non-current investing activities
Net cash flow from investing activities
---586.00K
Financing cash flow
Cash flow from continuous financing activities
---1.25M
Net cash flow from common stock issuance/repurchase
---1.25M
Proceeds from stock option exercised by employees
--0.00
Net cash flow from other financing activities
--0.00
Net cash from non-recurrent financing activities
Net cash from financing activities
---1.25M
Net cash flow
Beginning cash balance
--152.75M
Current period cash flow changes
---19.38M
Ending cash balance
--133.37M
Free cash flow
---18.13M
Currency unit
USD
Audit opinions
--
FAQs
What is the cash flow statement?
This report tracks the movement of cash into and out of the business, covering operating, investing, and financing activities. It highlights how well the company manages cash to support growth and meet its obligations.